YouTube & Expert Fact Checks
What experts say on YouTube vs what the clinical data actually shows.
Popular videos about retatrutide and GLP-1 drugs fact-checked claim-by-claim against published clinical trial data. When the video gets something right, we show the receipts. When it doesn't, we show that too.
Related topic hubs
- Retatrutide — The underlying retatrutide data
- Safety — Safety claims vs trial data
- Compare — Drug-vs-drug claims
How we fact-check
- Transcript. We pull the full video transcript and extract every factual claim — weight loss percentages, dosing schedules, mechanism descriptions, safety assertions, comparisons to other drugs.
- Source. Each claim is checked against primary sources: peer-reviewed journals (NEJM, Lancet, JAMA), the trial registration on ClinicalTrials.gov, and the sponsor's press releases and regulatory filings.
- Verdict per claim. We label each claim as supported, partially correct, misleading, or contradicted — and link to the underlying source.
- Context. Where the creator oversimplifies or adds context not in the trial, we flag it and add what the data actually shows.
Who gets reviewed
We focus on voices people are actively watching: physicians (Drs. Alex Tatem, Kevin Joseph, Dr. Dan), coaches and bodybuilding figures (Gary Miller, Nick Trigili, David DeMesquita, Colin Watson, Michael Morelli), podcasters (Andrew Huberman), and peptide-focused creators (JD Denham, Dave Nap, The Peptide Advantage).
Each review is structured the same way — creator's strongest claim, weakest claim, and overall accuracy read. Browse the full list below.
Reviews are editorial, not legal or medical advice. If we get a fact-check wrong ourselves, reach out via about and we'll update.
All fact checks articles
16 articles

Adrian Crook Quit Retatrutide After 6 Months: What He Learned
A 6-month retatrutide diary with DEXA data, craving elimination, and a PPI interaction warning.
Updated February 2026

Coach Colin Watson on Retatrutide: 12-Week Review vs What the Data Shows
Colin Watson's 12-week retatrutide review fact-checked — garbled mechanism, unsupported set point claims, and a peptide seller conflict of interest.
Updated February 2026

Coach Gary Miller on Retatrutide: His Protocol vs What the Data Shows
Gary Miller's retatrutide protocol fact-checked against Phase 2 and Phase 3 clinical data.
Updated February 2026

Dave Nap on CagriSema vs Tirzepatide, Novo Nordisk's Triple Agonist UBT-251, and Retatrutide: Fact Check
On The Pen host Dave Nap on CagriSema vs tirzepatide, Novo Nordisk triple agonist UBT-251, and retatrutide — fact-checked.
Updated February 2026

David DeMesquita's Retatrutide Injection Guide: What He Shows and What You Should Know
DeMesquita's retatrutide reconstitution and injection video analyzed with safety context.
Updated February 2026

Dr. Alex Tatem on Retatrutide: A Physician's Breakdown Fact-Checked
A physician's retatrutide explainer fact-checked — mechanism, Phase 2 data, drug comparisons, and FDA timeline.
Updated February 2026

Dr. Ashley Froese on Retatrutide: Why It's the "King" of Fat Loss Peptides, Fact-Checked
A physician's retatrutide explainer fact-checked — GIP futile calcium cycling, glucagon thermogenesis, muscle loss, allodynia, and dosing.
Updated April 2026

Dr. Dan on Retatrutide vs Ozempic: Obesity Expert Fact Check
Obesity expert Dr. Dan's retatrutide vs Ozempic comparison — Phase 2 data, side effects, and timeline predictions fact-checked.
Updated February 2026

Dr. Jones DC on Retatrutide Phase 3 Results (28.7% Weight Loss), Triple Agonist Mechanism, and Retatrutide vs Tirzepatide: Fact Check
Dr. Jones DC on retatrutide Phase 3 results, triple agonist mechanism, and retatrutide vs tirzepatide — fact-checked against trial data.
Updated February 2026

Dr. Kevin Joseph on Retatrutide: Physician's Overview Fact-Checked
Dr. Kevin Joseph's retatrutide overview fact-checked — solid mechanism explanation, a few errors on trial data, and side effect predictions contradicted by Phase 3.
Updated February 2026

JD Denham on Retatrutide: Triple Agonist Mechanism, Dosing, and Fat Loss Claims — Fact Check
Peptide of the Week hosts on retatrutide dosing, nausea, muscle loss, and fat burning — fact-checked against clinical data.
Updated February 2026

Michael Morelli on Retatrutide: Fact Check
Michael Morelli claims retatrutide is anabolic and boosts cognition — fact-checked against published data.
Updated February 2026

NBC TODAY on Foundayo (Oral GLP-1 Pill): Fact Check
TODAY called it Zepbound — it's actually Foundayo. Weight loss data and pricing are accurate. Full fact check inside.
Updated April 2026

Nick Trigili on Retatrutide: His 10-Week Protocol vs What the Data Shows
Trigili's 10-week retatrutide protocol fact-checked against TRIUMPH-4 clinical trial data.
Updated February 2026

Pathologist Dr. Amin Hedayat on Retatrutide: What He Said and What the Data Shows
A pathologist dismantles retatrutide piece by piece — mechanism, liver data, heart risks, and anhedonia fact-checked.
Updated April 2026

The Peptide Advantage Retatrutide Dosing Protocol: Fact Check
The Peptide Advantage's 3x/week retatrutide microdosing protocol contradicts all clinical trial data — fact-checked.
Updated February 2026